UAB0901: Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)
Study Details
Study Description
Brief Summary
The primary objective of this trial is to determine the response rate of single agent zoledronic acid using a composite of criteria including the EORTC modified RECIST criteria and the EORTC tumor response criteria for 18F-FDG PET scans.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
This pilot study will examine the effect of bisphosphonate (zoledronic acid) in patients with malignant mesothelioma. Evaluation will be limited to patients with standard (CT scans) and functional instruments (FDG PET Scans) of tumor assessment after the administration of standard doses of zoledronic acid (4 mg IV every 3 weeks). We will also explore the biologic effect of zoledronic acid in patients using new serum markers as well as several blood level markers.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Zometa Zometa (zoledronic acid) will be administered by infusion on Day 1 of a 3-week cycle followed by tumor assessment from CT and/or PET scans every 2 cycles. This will continue until progression of disease and/or intolerable toxicity. |
Drug: Zometa
Zoledronic acid will be administered IV on the first day of a 21 day cycle at a concentration of 4 mg. The treatment will take about 30-60 minutes with the infusion lasting about 15 minutes.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Tumor Response Rate Following Zoledronic Acid (Zometa) [Baseline up to 28 months or until progressive disease or death]
The modified Response Evaluation Criteria in Solid Tumors Criteria (RECIST 2004) will be used for target lesions and assessed by CT scans. Complete Response (CR) is the disappearance of target lesions; Partial Response (PR) is greater than or equal to 30% reduction in the total tumor measurement; Stable Disease (SD) is the absence of response or progression; and Progressive Disease (PD) is a 20% increase in the total tumor measurement over nadir value or the appearance of new lesions.
Secondary Outcome Measures
- Progression Free Survival (PFS) [Baseline up to 28 months]
Progression Free Survival is defined as the number of days from the day the subject started treatment to the day the subject experienced evidence of disease progression, as determined by radiological or clinical progression.
- Overall Survival (OS) [Baseline up to 28 months]
Overall Survival is defined as the number of days from the day the subject started treatment to the day the subject experienced death or lost to follow-up.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Males and females > 18 years of age
-
Life expectancy of at least 2 months
-
Histologically confirmed unresectable malignant pleural mesothelioma (MPM)
-
Measurable disease by CT Scan criteria and/or positive metabolic activity of 18F-FDG PET Scan criteria at screening
-
ECOG Performance Status of 0-2
-
Laboratory and clinical results within 2 weeks prior to Day 1 must be as follows:
-
ANC ≥ 1.5 x 109/L
-
Platelet Count ≥ 100 x 109/L
-
Hemoglobin ≥ 9g/dL
-
Serum bilirubin ≤ 1.5 x upper limit of normal (ULN)
-
AST ≤ 2.5 x ULN
-
ALT ≤ 2.5 x ULN
-
ALK-P ≤ 3 x ULN
-
Serum creatinine ≤ 1.8mg/dL
-
Calculated Serum Creatinine Clearance 40 - > 60ml/min
-
Female subjects of childbearing potential and all male subjects must be surgically sterile or consent to use a medically acceptable method of contraception throughout the trial.
-
Willing and able to provide written informed consent.
Exclusion Criteria:
-
Known central nervous system (CNS) tumor involvement
-
Evidence of other active malignancy requiring treatment
-
Clinically significant heart disease (e.g., congestive heart failure of New York Heart Association Class 3 or 4 angina not well controlled by medication, or myocardial infarction within 6 months)
-
Known infection with HIV or hepatitis
-
Clinically significant arrhythmias demonstrated on electrocardiogram (ECG). Note: subjects with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia (SVT) are eligible.
-
Active, serious systemic disease, including active bacterial or fungal infection.
-
Subjects undergoing invasive dental procedures, significant periodontal disease or history of osteonecrosis of the jaw.
-
Treatment within 4 weeks of the start of the trial with other systemic anticancer therapy.
-
Breastfeeding, pregnant, or likely to become pregnant during the clinical trial.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Alabama at Birmingham | Birmingham | Alabama | United States | 35294 |
Sponsors and Collaborators
- University of Alabama at Birmingham
- Novartis Pharmaceuticals
Investigators
- Principal Investigator: Francisco Robert, M.D., University of Alabama at Birmingham
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- F090917002 (UAB 0901)
- UAB 0901
Study Results
Participant Flow
| Recruitment Details | Inclusion criteria included: adult patients (age>18) with unresectable Malignant Pleural Mesothelioma (MPM) who had progressed after one or more prior systemic therapies, had not received prior systemic therapy due to poor performance status (PS), and/or were unwilling to receive systemic chemotherapy. |
|---|---|
| Pre-assignment Detail | The primary objective of this study was to evaluate the anti-tumor activity of zoledronic acid (Zometa) in subjects with unresectable, advanced Malignant Pleural Mesothelioma (MPM). |
| Arm/Group Title | Zoledronic Acid (Zometa) |
|---|---|
| Arm/Group Description | Zoledronic acid (Zometa) will be administered by infusion on Day 1 of a 3-week cycle followed by tumor assessment from CT and/or PET scans every 2 cycles. This will continue until progression of disease and/or intolerable toxicity. Zoledronic acid (Zometa) will be administered IV on the first day of a 21 day cycle at a concentration of 4 mg. The treatment will take about 30-60 minutes with the infusion lasting about 15 minutes. |
| Period Title: Overall Study | |
| STARTED | 8 |
| COMPLETED | 8 |
| NOT COMPLETED | 0 |
Baseline Characteristics
| Arm/Group Title | Zoledronic Acid (Zometa) |
|---|---|
| Arm/Group Description | Zometa (zoledronic acid) 4mg will be administered by infusion on Day 1 of a 3-week cycle followed by tumor assessment from CT and/or PET scans every 2 cycles. This will continue until progression of disease and/or intolerable toxicity. |
| Overall Participants | 8 |
| Age (years) [Median (Full Range) ] | |
| Median (Full Range) [years] |
62
|
| Sex: Female, Male (Count of Participants) | |
| Female |
0
0%
|
| Male |
8
100%
|
| Region of Enrollment (participants) [Number] | |
| United States |
8
100%
|
Outcome Measures
| Title | Tumor Response Rate Following Zoledronic Acid (Zometa) |
|---|---|
| Description | The modified Response Evaluation Criteria in Solid Tumors Criteria (RECIST 2004) will be used for target lesions and assessed by CT scans. Complete Response (CR) is the disappearance of target lesions; Partial Response (PR) is greater than or equal to 30% reduction in the total tumor measurement; Stable Disease (SD) is the absence of response or progression; and Progressive Disease (PD) is a 20% increase in the total tumor measurement over nadir value or the appearance of new lesions. |
| Time Frame | Baseline up to 28 months or until progressive disease or death |
Outcome Measure Data
| Analysis Population Description |
|---|
| Participants with advanced malignant pleural mesothelioma. |
| Arm/Group Title | Zometa |
|---|---|
| Arm/Group Description | Zometa (zoledronic acid) will be administered by infusion on Day 1 of a 3-week cycle followed by tumor assessment from CT and/or PET scans every 2 cycles. This will continue until progression of disease and/or intolerable toxicity. Zometa: Zoledronic acid will be administered IV on the first day of a 21 day cycle at a concentration of 4 mg. The treatment will take about 30-60 minutes with the infusion lasting about 15 minutes. |
| Measure Participants | 8 |
| Number [percentage of responders] |
12.5
|
| Title | Progression Free Survival (PFS) |
|---|---|
| Description | Progression Free Survival is defined as the number of days from the day the subject started treatment to the day the subject experienced evidence of disease progression, as determined by radiological or clinical progression. |
| Time Frame | Baseline up to 28 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| Participants with advanced malignant pleural mesothelioma. |
| Arm/Group Title | Zometa |
|---|---|
| Arm/Group Description | Zometa (zoledronic acid) will be administered by infusion on Day 1 of a 3-week cycle followed by tumor assessment from CT and/or PET scans every 2 cycles. This will continue until progression of disease and/or intolerable toxicity. Zometa: Zoledronic acid will be administered IV on the first day of a 21 day cycle at a concentration of 4 mg. The treatment will take about 30-60 minutes with the infusion lasting about 15 minutes. |
| Measure Participants | 8 |
| Median (Full Range) [Months] |
2
|
| Title | Overall Survival (OS) |
|---|---|
| Description | Overall Survival is defined as the number of days from the day the subject started treatment to the day the subject experienced death or lost to follow-up. |
| Time Frame | Baseline up to 28 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| Participants with advanced malignant pleural mesothelioma. |
| Arm/Group Title | Zometa |
|---|---|
| Arm/Group Description | Zometa (zoledronic acid) will be administered by infusion on Day 1 of a 3-week cycle followed by tumor assessment from CT and/or PET scans every 2 cycles. This will continue until progression of disease and/or intolerable toxicity. Zometa: Zoledronic acid will be administered IV on the first day of a 21 day cycle at a concentration of 4 mg. The treatment will take about 30-60 minutes with the infusion lasting about 15 minutes. |
| Measure Participants | 8 |
| Median (Full Range) [months] |
7
|
Adverse Events
| Time Frame | From baseline to 28 months | |
|---|---|---|
| Adverse Event Reporting Description | Subjects with either stable disease or objective response continued treatment until disease progression and/or intolerable toxicity at which patients were taken off study. Subjects were monitored for toxicity using NCI CTAE v3.0 Criteria. Dose adjustment was allowed per standard guidelines for zoledronic acid for decreased creatinine clearance. Patients who completed at least one treatment cycle were included in data analysis. | |
| Arm/Group Title | Zoledronic Acid (Zometa) | |
| Arm/Group Description | Zoledronic acid (Zometa) will be administered IV-4mg by infusion on Day 1 of a 3-week cycle followed by tumor assessment from CT and/or PET scans every 2 cycles.The treatment will take about 30-60 minutes with the infusion lasting about 15 minutes.This will continue until progression of disease and/or intolerable toxicity. | |
All Cause Mortality |
||
| Zoledronic Acid (Zometa) | ||
| Affected / at Risk (%) | # Events | |
| Total | 0/8 (0%) | |
Serious Adverse Events |
||
| Zoledronic Acid (Zometa) | ||
| Affected / at Risk (%) | # Events | |
| Total | 0/8 (0%) | |
Other (Not Including Serious) Adverse Events |
||
| Zoledronic Acid (Zometa) | ||
| Affected / at Risk (%) | # Events | |
| Total | 0/8 (0%) | |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Francisco Robert, MD |
|---|---|
| Organization | University of Alabama at Birmingham |
| Phone | 205-934-5077 |
| pacorobertuab@cs.com |
- F090917002 (UAB 0901)
- UAB 0901